Fig. 7: Emergence of IDH1/FLT3/NRAS clones during IDH2 inhibitor-containing therapy. | Nature Communications

Fig. 7: Emergence of IDH1/FLT3/NRAS clones during IDH2 inhibitor-containing therapy.

From: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Fig. 7

A 76-year old woman with AML showing the parallel evolution of IDH1 p.R132C, FLT3-ITD, NRAS p.G60E, and PTPN11 p.I282V clones during an IDH2 inhibitor-containing therapy. Clad cladribine, LDAC low dose cytarabine, Ena enasidenib, VEN venetoclax, DAC decitabine. The fish plot shows the inferred clonal evolution pattern based on the single-cell genotype data. The phylogenetic trees visualize the estimated order of mutation acquisition and the proportion of subclones with a different combination of mutations at each timepoint. The wild-type cells which did not carry any driver mutations are not shown. BL baseline, CR complete remission, C cycle, D day, REL relapse, ADO allele dropout, FPR false-positive rate. Full case description is available in Supplementary Methods.

Back to article page